Patents
Mammary stem cell marker
Patent Number: 7,563,619Cancer stem cells are considered the "Seed" or the "root" of the cancer, and like chopping down a tree, if you dont remove the root, the cancer grows back. Cancer stem cells are resistant to chemotherapy and radiotherapy. Therefore if there was a way to selectively purify or extract cancer stem cells, it would make it a lot easier...
Inventors: Williams; Bart (Grand Rapids, MI), Alexander; Caroline M. (Madison, WI), Lindvall; Charlotta (Grand Rapids, MI), McConnell; Nisha (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation (Madison, WI)
Date of First Priority Issue: Tuesday May 30th, 2006
Soft tissue repair and regeneration using postpartum-derived cells
Patent Number: 7,560,276Despite the fact the Celgene through Bob Hariri owns the majority of the placental tissue cells, this patent, assigned to Ethicon, seems to circumvent some of the Celgene claims and covers use of CD117 negative cells from placenta for wound healing.The patent covers a method of stimulating soft tissue infiltration in a tissue defect by adding umbilical...
Inventors: Harmon; Alexander M. (Clinton, NJ), Harris; Ian Ross (Belle Mead, NJ), Kihm; Anthony J. (Princeton, NJ), Mistry; Sanjay (Bedminster, NJ), Messina; Darin J. (Somerville, NJ), Seyda; Agnieszka (New Brunswick, NJ), Yi; Chin-Feng (Hillsborough, NJ), Gosiewska
Assignee: Ethicon, Inc. (Somerville, NJ)
Date of First Priority Issue: Friday June 27th, 2003
Compositions and methods for generating skin
Patent Number: 7,560,275This patent covers a mammalian cell that has properties of spores and is useful for regeneration of new skin. Its first independent claim is:A population of isolated mammalian or avian multipotent spore-like cells (MSLCs) isolated or cultured from skin tissue and which can differentiate into two or more mature skin cell type cells. wherein the MSLCs, when first isolated, are approximately...
Inventors: Vacanti; Martin P. (Westborough, MA), Vacanti; Charles A. (Uxbridge, MA)
Assignee: VBI Technologies, L.L.C. (Houston, TX)
Date of First Priority Issue: Thursday December 30th, 1999
Method for reducing neuronal degeneration so as to ameliorate the effects of injury or disease
Patent Number: 7,560,102This patent teaches methods of stimulating nervous system regeneration by activating an immune response against the nervous system. Specifically, stimulation of immunity against antigens in the central nervous system such as myelin is associated with induction of autoimmunity, for example in the animal model of multiple sclerosis called experimental allergic...
Inventors: Eisenbach-Schwartz; Michal (Rehovot, IL), Hauben; Ehud (Rehovot, IL), Cohen; Irun R. (Rehovot, IL), Beserman; Pierre (Moshav Sitriya, IL), Monsonego; Alon (Rehovot, IL), Moalem; Gila (Petah-Tiqva, IL)
Assignee: Yeda Research and Development Co. Ltd. (Rehovot, IL)
Date of First Priority Issue: Tuesday July 21st, 1998
Human cord blood derived unrestricted somatic stem cells (USSC)
Patent Number: 7,560,280This is the composition of matter patent for the unrestricted somatic stem cell (USSC) that was under development by Viacell. These cells appear to have pluripotent properties as listed in the examples section. The first independent claim of the patent covers:"An isolated unrestricted somatic stem cell (USSC) prepared from human umbilical cord blood or placental blood, wherein said USSC...
Inventors: Wernet; Peter (Dusseldorf, DE)
Assignee: Viacell, Inc. (Worcester, MA)
Date of First Priority Issue: Friday November 3rd, 2000
Human cord blood derived unrestricted somatic stem cells (USSC)
Patent Number: 7,556,801An argument made in the popular media is that adult stem cells are healing people "today", whereas embryonic stem cells are a thing of the future. In priniciple this is correct, however, my stomach turns when the proponents of adult stem cells use the example of "bone marrow transplantation". Bone marrow transplantation, while it is a sort of "stem cell...
Inventors: Wernet; Peter (Dusseldorf, DE)
Assignee: Viacell, Inc. (Worcester, MA)
Date of First Priority Issue: Friday November 3rd, 2000
Stromal antigen-presenting cells and use thereof
Patent Number: 7,553,661Mesenchymal stem cells are known to possess a variety of immune modulatory activities such as suppression of allogeneic responses, as well as induction of T regulatory cells. Mechanisms include expression of IDO and HLA-G. Mesenchymal stem cells have been demonstrated effective in patients with
Assignee: McGill University (Montreal, CA)
Date of First Priority Issue: Tuesday May 31st, 2005
Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
Patent Number: 7,553,663This patent is a continuation of Blasticon's #7,138,275 covering a monocyte-derived stem cell that is capable of differentiating into islets, hepatocytes, and neurons. In the current patent the use of hepatic, or hepatic-like cells derived from these monocytes is covered.The general coverage of the patent extends to generation and use of a cell capable...
Inventors: Kremer; Bernd Karl Friedrich (Kiel, DE), Fandrich; Fred (Kiel, DE), Ruhnke; Maren nee Schulze (Kiel, DE)
Assignee: Blasticon Biotechnologische Forschung GmbH (Keil, DE)
Date of First Priority Issue: Thursday March 28th, 2002
Directed in vitro differentiation of marrow stromal cells into neural cell progenitors
Patent Number: 7,547,545This patent covers the generation of neurons from mesenchymal stem cells, or like the inventor calls them "mesenchymal stromal cells", which is the more politically correct way of naming them.Very broad claims are issued, the first one being: "A method of producing a neural progenitor cell, said method comprising contacting an isolated bone...
Inventors: Prockop; Darwin J. (New Orleans, LA), Deng; Weiwen (Metairie, LA)
Assignee: Not Stated
Date of First Priority Issue: Wednesday May 30th, 2001
Progenitor cells from wharton's jelly of human umbilical cord
Patent Number: 7,547,546This patent covers methods of extracting an adherent mesenchymal-like stem cells from the Wharton's Jelly of the umbilical cord. The extracted cells are negative for MHC and are termed by the inventors human umbilical cord perivascular (HUCPV) cells. In the examples section the the cells are demonstrated to be capable of differentiating into osteocytes, chondrocytes, adipocytes, and...
Inventors: Davies; John E. (Toronto, CA), Baksh; Dolores (Mississauga, CA), Sarugaser; Rahul (Toronto, CA), Hosseini; Morris (Braunschweig, DE), Lickorish; Antony D. S. (Toronto, CA)
Assignee: Tissue Regeneration Therapeutics Inc. (Toronto, Ontario, CA)
Date of First Priority Issue: Tuesday February 11th, 2003